Stuttgart - Delayed Quote EUR

Incyte Corp (ICY.SG)

66.72

+0.76

+(1.15%)

At close: 9:54:26 PM GMT+1

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte ( NASDAQ:INCY ) Full Year 2024 Results Key Financial Results Revenue: US$4.24b (up 15% from FY 2023). Net...

Simply Wall St. 2 days ago

INCY
Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

Incyte Corp (INCY) reports a 15% revenue increase for 2024, driven by robust sales of Jakafi and Opzelura, while maintaining a solid cash position and outlining ambitious 2025 guidance.

GuruFocus.com 2 days ago

INCY
Q4 2024 Incyte Corp Earnings Call

Q4 2024 Incyte Corp Earnings Call

Thomson Reuters StreetEvents 2 days ago

INCY
S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update

The S&P 500 gained 0.7% on Monday, Feb. 10, as investors weighed the impact of additional tariffs on imported metals and awaited more earnings updates.

Investopedia 3 days ago

^GSPC

SMCI

WDC
Incyte Reports 2024 Financial Results and Outlines 2025 Projections

$1.2 billion in Q4 2024, a 16% year-over-year increase; $4.2 billion for the full year, up 15% from 2023.

GuruFocus.com 3 days ago

INCY
Why Incyte (INCY) Shares Are Plunging Today

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 8.9% in the morning session after the company reported fourth-quarter results with full-year guidance for key products such as Jakafi and Opzelura, indicating a significant deceleration in growth. Also, earnings fell short of expectations during the quarter, suggesting profit might be under pressure. On the other hand, revenue exceeded expectations, but markets tend to focus more on the long term. Overall, this quarter cou

StockStory 3 days ago

INCY
Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' estimates.

Investopedia 3 days ago

INCY
INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte reports mixed fourth-quarter 2024 results as earnings miss estimates while revenues beat the same. Jakafi and Opzelura drive year-over-year sales.

Zacks 3 days ago

INCY

LLY
Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches

On Monday, Incyte Corporation (NASDAQ:INCY) reported fourth-quarter revenue of $1.18 billion, up 16% year over year and beating the consensus of $1.14 billion. The company reported an adjusted EPS of $1.43, which was up from $1.06 a year ago and missing the consensus estimate of $1.56. Jakafi’s net product revenue increased 11% to $773.1 million, primarily due to a 14% increase in paid demand. Also Read: Incyte At JPM25: Eyes Transformational 2025 With Multiple Drug Launches And Expanding Pipeli

Benzinga 3 days ago

INCY
Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 3 days ago

INCY
Incyte forecasts downbeat annual sales of skin disease drug, shares fall

(Reuters) -Incyte Corp on Monday forecast annual sales of its skin disorder treatment Opzelura below Wall Street estimates, sending the drugmaker's shares down as much as 9% in afternoon trade. Opzelura is used for the treatment of skin conditions called vitiligo and mild-to-moderate atopic dermatitis in patients 12 years and older. Incyte expects Opzelura sales in 2025 to be between $630 million and $670 million.

Reuters 3 days ago

INCY
Incyte (INCY) Q4 Earnings Miss Estimates

Incyte (INCY) delivered earnings and revenue surprises of -6.54% and 2.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 days ago

INCY
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2024, with sales up 16.3% year on year to $1.18 billion. Its non-GAAP profit of $1.43 per share was 8% below analysts’ consensus estimates.

StockStory 3 days ago

INCY
Incyte: Q4 Earnings Snapshot

WILMINGTON, Del. AP) — Incyte Corp. INCY) on Monday reported fourth-quarter profit of $201.2 million.

Associated Press Finance 3 days ago

INCY
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

WILMINGTON, Del., February 10, 2025--Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Business Wire 3 days ago

INCY
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting earnings tomorrow before the bell. Here’s what to expect.

StockStory 4 days ago

INCY

REGN

ABBV
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., February 07, 2025--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 6 days ago

INCY
Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 7 days ago

BPMC

INCY
Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Incyte (INCY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Zacks 8 days ago

INCY
Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

INCY's fourth-quarter 2024 earnings are likely to have gained from higher Jakafi and Opzelura sales.

Zacks 9 days ago

INCY

NVS

Performance Overview

Return	ICY.SG	S&P 500
YTD	+1.28%	+3.97%
1-Year	+23.92%	+23.46%
3-Year	+14.25%	+38.39%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Incyte Corp (ICY.SG)

Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook

Q4 2024 Incyte Corp Earnings Call

S&P 500 Gains and Losses Today: Supermicro Stock Surges Ahead of Business Update

Incyte Reports 2024 Financial Results and Outlines 2025 Projections

Why Incyte (INCY) Shares Are Plunging Today

Incyte Stock Sinks as Sales Forecast for Key Drugs Falls Short

INCY's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Incyte Q4 Earnings: EPS Miss, Strong Jakafi And Opzelura Sales, Says 2025 To Be Catalyst Rich Including 4 Launches

Incyte (INCY) Reports Q4 Earnings: What Key Metrics Have to Say

Incyte forecasts downbeat annual sales of skin disease drug, shares fall

Incyte (INCY) Q4 Earnings Miss Estimates

Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q4

Incyte: Q4 Earnings Snapshot

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D Milestones

Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Will Blueprint Medicines (BPMC) Report Negative Earnings Next Week? What You Should Know

Curious about Incyte (INCY) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Incyte Gears Up to Report Q4 Earnings: Here's What You Should Know

Performance Overview